A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
University of Wisconsin, Madison
Mclean Hospital
Exelixis
National Institutes of Health Clinical Center (CC)
Milton S. Hershey Medical Center
Incyte Corporation
Geisinger Clinic
St. Joseph's Hospital and Medical Center, Phoenix
Incyte Corporation
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
Alaunos Therapeutics
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
University of Oklahoma
Alaunos Therapeutics
Alliance for Clinical Trials in Oncology
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Amgen
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Basilea Pharmaceutica
Duke University
Providence Health & Services
Novartis
University of Nebraska
Rush University Medical Center
Duke University
Baptist Health South Florida
Karyopharm Therapeutics Inc
Brown University
Indiana University
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
University of Florida
Boston Scientific Corporation
Duke University
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Proximagen, LLC
Diffusion Pharmaceuticals Inc
RTOG Foundation, Inc.
AbbVie
SynerGene Therapeutics, Inc.
Pediatric Brain Tumor Consortium
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)